Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.
Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Zai Lab Limited (NASDAQ: ZLAB) announced a strategic partnership with MediLink Therapeutics, acquiring an exclusive worldwide license for YL212, a novel DLL3 ADC aimed at treating lung cancer. This collaboration enhances Zai Lab's oncology pipeline and lung cancer franchise, as YL212 is developed using MediLink’s proprietary TAMLIN® platform. The DLL3 target is overexpressed in small cell lung cancer (SCLC), indicating significant potential for addressing unmet medical needs. Zai Lab will oversee global development and commercialization, with MediLink receiving milestone payments and royalties. The partnership reflects Zai Lab's strategic focus on innovative cancer therapies and complements its existing lung cancer portfolio, which includes the recently approved TIVDAK for cervical cancer.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that the results from the phase 3 LUNAR clinical trial in metastatic non-small cell lung cancer (NSCLC) will be presented at the upcoming ASCO Annual Meeting from June 2 to June 6, 2023. Conducted by their partner NovoCure Limited, the trial evaluates the combination of Tumor Treating Fields (TTFields) therapy with standard treatments after prior platinum-based therapy. Notably, the trial met its primary endpoint, showing a statistically significant improvement in overall survival when TTFields was combined with standard therapies. This presentation represents a significant advancement in addressing the unmet needs of lung cancer patients, especially in China, where around 700,000 new NSCLC cases are diagnosed annually. The presentation will occur on June 6 at 11:09 a.m. CDT, marking a pivotal moment for Zai Lab in the oncology landscape.
Zai Lab Limited (NASDAQ: ZLAB) will report its Q1 2023 financial results on May 9, 2023, after U.S. market close. A conference call and webcast will follow on May 10, 2023, at 8:00 a.m. ET. The company focuses on innovative biopharmaceuticals addressing significant unmet medical needs in areas like oncology and infectious diseases. Stakeholders can access the live event through the company’s website.
As Zai Lab prepares for the conference, the press release emphasizes their commitment to enhancing health worldwide through research and product development.